Core Viewpoint - SK bioscience has achieved a significant legal victory in a patent infringement lawsuit against Pfizer, allowing the company to expand its operations in the pneumococcal vaccine market [1][2][7] Group 1: Legal Developments - The Supreme Court of Korea ruled in favor of SK bioscience, stating that the individual conjugates of its 13-valent pneumococcal conjugate vaccine (PCV13) do not infringe on Pfizer's patent claims [2] - The court confirmed that the production and supply of PCV13 finished products for research purposes do not constitute patent infringement [2] - SK bioscience has also successfully invalidated a patent held by Moderna related to mRNA vaccine technology, which is seen as a major step in reducing patent-related risks for domestic companies [7] Group 2: Business Expansion Plans - Following the court ruling, SK bioscience plans to export individual components of PCV13 to countries with high vaccine demand, particularly in Southeast Asia and Latin America [4] - The company aims to expand its presence in the global pneumococcal vaccine market, with plans to manufacture and sell its vaccine SKYPneumo domestically starting in 2027 [5] - SK bioscience is developing a 21-valent pneumococcal conjugate vaccine in collaboration with Sanofi, which is currently in Phase 3 global clinical trials [5] Group 3: Market Outlook - The global pneumococcal vaccine market is projected to grow at a compound annual growth rate of approximately 5.6%, reaching USD 15.1 billion (approximately KRW 21.55 trillion) by 2034 [6] - This growth is driven by expanded vaccination programs and support from governments and international organizations [6] - SK bioscience's strong track record in public vaccine supply positions it well for future expansion in this growing market [6]